Abstract 1
Human induced pluripotent stem cells (hiPSCs) represent an ideal in vitro platform to study 2 human genetics and biology. The recent advent of programmable nucleases makes also the 3 human genome amenable to experimental genetics through either the correction of 4 mutations in patient-derived iPSC lines or the de novo introduction of mutations into 5 otherwise healthy iPSCs. The production of specific and sometimes complex genotypes in 6 multiple cell lines requires efficient and streamlined gene editing technologies. In this article 7
we provide protocols for gene editing in hiPSCs. We presently achieve high rates of gene 8 editing at up to three loci using a modified iCRISPR system. This system includes a 9 doxycycline inducible Cas9 and sgRNA/reporter plasmids for the enrichment of transfected 10 cells by fluorescence-activated cell sorting (FACS). Here we cover the selection of target 11 sites, vector construction, transfection, and isolation and genotyping of modified hiPSC 12 clones. 13 14
Introduction 15
Human induced pluripotent stem cells (hiPSCs) represent an ideal platform to study human 16 genetics and biology in vitro [1, 2] . Induced pluripotent stem cell lines can be established by 17
reprogramming of somatic cells from any healthy or diseased individual [3] , being able to 18 embody the diversity of genotypes within the human population. Since hiPSCs are self-19 renewing they can be propagated indefinitely in the pluripotent state but on demand 20 differentiated into selected cell types such as neurons [4] or cardiomyocytes [5] . 21
The strength of non-human model organisms is based on in vivo analysis and the availability 22 of reverse and forward genetic tools enabling functional genomics studies which unravel 23 genotype to phenotype connections, including disease related variants. The recent advent of 24 programmable nucleases makes also the human genome amenable to experimental 25 genetics through either the correction of mutations in patient-derived iPSC lines or the de 26 novo introduction of mutations into otherwise healthy iPSCs [6, 7] . Some heritable diseases 27 are strictly monogenetic, but observable phenotypes often depend on epistatic interaction 28 from multiple genes. An understanding of disease-specific epistasis will improve the 29 prediction of disease risks and elucidate disease mechanisms, e.g. distinguishing between 30 disease specifiers and modifiers [8, 9] . In animal genetics genotypes and backgrounds can be 31 constructed and manipulated by breeding and backcrossing. In hiPSCs the genome is fixed, 32 so studies investigating the effects of human genetic diversity require the use of multiple cell 33 lines side-by-side. 34 guide (sg)RNA to home the Cas9 nuclease. A DNA repair template is often additionally 48 provided to allow for homology directed repair (HDR). The first twenty nucleotides of sgRNAs 49 direct Cas9 to a specified complementary DNA target sequence via RNA-DNA hybridization. 50
The target sequence is always located upstream of an invariant protospacer adjacent motif 51
(PAM) sequence (NGG for SpCas9 from Streptococcus pyogenes). Upon correct 52
hybridization the Cas9 nuclease undergoes a conformational change and creates a DSB 53 located 3 bp upstream of the PAM site (Fig.1A, B ) [14] . An advantage of the CRISPR/Cas9 54 system is that the Cas9 protein component is of universal use and new target sites can be 55 easily targeted by addition of a new sgRNA sequence. The gene editing process follows 56 induction of DSBs where DNA repair pathways result in deletion, replacement or insertion of 57
sequences. 58
Two main DNA repair pathways exist in mammalian cells. In most instances DSBs 59 are repaired by the non-homologous end joining (NHEJ) pathway. NHEJ religates open DNA 60 ends using DNA ligase IV without using a repair template [15] . DSBs processed by the NHEJ 61 pathway frequently exhibit random small deletions and/or insertions of nucleotides (indels) 62 (Fig. 1C) . Within coding regions this results in frameshift (knockout) mutations in the majority 63 of cases. Alternative to NHEJ, DSBs can be repaired by HDR and requires a DNA molecule 64 as repair template [16, 17] . The natural endogenous use of HDR is for spontaneously 65 occurring DSBs. Cycling cells use the intact homologous region of the sister chromatid as 66 HDR template. To achieve precise sequence modifications at targeted DSBs, the HDR 67 pathway can be exploited to copy in a sequence of interest. This is done through the addition 68 of an artificial DNA template which mimics the sister chromatid by including homology 69 sequences located up-and downstream of the DSB and concurrently flanking a desired 70 sequence modification or insertion [18] . In the repair process gene conversion extends from 71 the template`s homology regions into the heterologous sequence and also transfers the 72 modified region into the target sequence (knockin), enabling to introduce precise mutations 73 such as codon replacements or the insertion of reporter genes (Fig. 1C) . Large sequence 74 insertions require the construction of plasmid-based gene targeting vectors which include 75 homology regions of > 1000 bp, whereas small sequence modifications can be introduced by 76 using synthetic single-stranded DNA oligonucleotides (ssODN) with lengths of 100-150 nt. In 77 cycling cells both repair mechanisms work side by side, but most DSBs are repaired by the 78 prevailing NHEJ pathway whereas HDR occurs less frequently. hiPSCs can serve as a paradigm for the feasibility of future cell based therapies. The 100 CRISPR/Cas9 system can be used for modification of both copies of a target gene, or 101 restricted to induce changes only in alleles of interest by selective gene editing based on 102 haplotype-specific target sites [22] [23] [24] [25] . 103
Gene editing in hiPSCs and other cells is now routinely performed using the 104 in hiPSC. This approach was first described in hiPSCs as the doxycycline inducible iCRISPR 158 system which just requires the transfection of multiple sgRNAs and allows the knockout of up 159 to three genes in a single step [19] . Depending on the experimental setup, both classical 160 CRISPR/Cas9 and the iCRISPR system feature advantages and drawbacks. The former is 161 applicable to wildtype cells if no further genomic modifications are desired, e.g. experimental 162
(re-)engraftments. The latter was demonstrated to provide improved efficacy when applied to 163 modify multiple loci, although prior cell line generation is required and a modified AAVS1 164 locus will remain if no strategies for final Cas9 gene removal are applied. 165
In this protocol we include two ways to achieve gene editing in hiPSCs. Both describe 166 detailed procedures on how to introduce CRISPR/Cas9-mediated, site-specific DSBs 167 followed by suggestions for analysis of resulting indel formations. These methods can further 168 provide a framework for HDR-mediated insertion. 169
The first approach, enables editing of single genes by transfection of a vector 170 encoding Cas9 and sgRNA (cloned into pU6-(BbsI)sgRNA_CAG-Cas9-bpA_EF1-TagRFP or 171 pU6-(BbsI)sgRNA_CAG-Cas9-venus-bpA, section 3. target sequence (such as GC content) influences the nuclease activity of Cas9 at the target 212 site (on-target activity), as well as the probability that Cas9 cuts other related sites within the 213 genome (off-target activity). To analyze all sgRNAs for their on-target efficiency and off-target 214 sites we prefer to use the CRISPOR website (http://crispor.tefor.net/) [40] . CRISPOR 215 provides scores for the specificity of sgRNAs as well as on-target efficiency using meta-216 analysis of all published activity ranking tools. Various studies suggest that off-target sites of 217 RNA-guided Cas9 nucleases can be variable in frequency, challenging to predict and it is not 218 possible to predict how many mismatches can be tolerated [26] . Nevertheless, a careful 219 selection among the target sequences addressing a given genomic region of interest will 220 reduce the risk of creating off-target mutations. Therefore, we recommend to use only 221 sgRNAs showing the highest specificity scores and to save the information on potential off-222 target sites for later PCR analysis (see section 3.5.8). 223
Genetic editing resulting in the generation of a knockin, being either an insertion or a regional 224 replacement, is achieved by HDR. To generate such a targeted sequence modification, the 225 sgRNA target site should be located close (< 100 bp) to the position of the intended mutation 226 as the frequency of sequence conversion by HDR decreases with distance. Targeted 227 mutations by HDR are guided by repair templates, being either ssODNs or plasmid gene 228 targeting vectors [14, 41] . ssODNs are convenient as they are synthetized for a reasonable 229 price so that cloning work is not required. ssODNs used as HDR template contain a short 230 sequence modification (deletion, insertion or substitution) flanked by two homology 231 sequences. Many manufacturers of custom ssODNs offer lengths up to 150 nt or more, 232 enabling the insertion of sequences of up to ~50 nt. When using ssODNs we recommend the 233 selection of target sites that are less than 10 bp distant to the planned mutation. In the 234 standard design, as their length is limited, a desired mutation is located at the center of an 235 ssODN, resulting in similarly-sized homology regions (usually 40-60 nt each) that flank the 236 desired mutation symmetrically on both sides. It is crucial to avoid the recognition and 237 recleaving of the recombined allele by Cas9 by the inclusion of one or more silent nucleotide 238 replacements to destroy the PAM recognition site. Silent mutations can be added to facilitate 239 later screening for successful recombination, e.g. by the introduction of a recognition site for 240 restriction enzymes for restriction fragment length polymorphism (RFLP). 241
Recent studies suggest that choice of the target strand and an asymmetric design of 242 ssODNs increase the knockin efficiency [42] and that phosphorothioate (PTO) modifications 243 improve stability and HDR efficacy [43] . However, it was not shown if these rules apply to 244 hiPSCs as well. We have performed a side by side evaluation of ssODNs with symmetric or 245 asymmetric structure with or without PTO modifications (Fig. 3 ). Analogously to Glaser et al. 246
[44], we used human iPS cells heterozygously expressing a CAG promoter driven EGFP 247 from the AAVS1 locus as a reporter system for HDR. The EGFP gene was targeted with a 248 sgRNA to induce a DSB. By homologous recombination of donor templates that substitute 4 249 bp, the original green fluorescent EGFP is converted to blue fluorescent BFP and the PAM 250 sequence rendered non-functional, as previously reported [44] . Based on this assay, we 251 observed that in hiPSCs unmodified ssODNs without PTO modifications yield higher HDR 252 rates compared to modified ones ( 
Cloning of sgRNAs 381
This protocol recommends the usage of either plasmid pU6-(BbsI)sgRNA_CAG-Cas9-382 venus-bpA or pU6-(BbsI)sgRNA_CAG-Cas9_EF1-TagRFP (Workflow A), encoding for 383 sgRNA and Cas9 and a fluorescent Venus or RFP reporter, or usage of pU6-384 (BbsI)sgRNA_CAG-venus-bpA, carrying a sgRNA-cassette and a fluorescent reporter only 385 (Workflow B). These vectors allow expression of the sgRNA by the human U6-promoter. This 386 promoter requires a "G" base at the transcription start site. Hence, it is recommended using 387 CRISPR/Cas9 target sites starting with a "G". Otherwise an additional "G" should be added 388 at the start of the sgRNA sequence. It should be noted that wildtype Cas9 is amenable to 389 the inclusion of an extra "G" but other RNA guided nucleases are not (Cas9-HF/eCas9). All 390 three above mentioned plasmids together with their maps and sequences are deposited at 391 Addgene (www.addgene.org) which also provides a wide range of other vector systems for 392
Cas9 expression and sgRNA cloning. 
Cloning of multiple sgRNAs 452
To clone multiple sgRNA expression cassettes in pU6-(BbsI)sgRNA_CAG-venus-bpA via 453
Gibson assembly, the individual sgRNAs have to be cloned separately beforehand as 454 previously described in section 3.1.1. These single sgRNA plasmids serve as template for 455 amplifying a specific sgRNA cassettes including overlapping ends for Gibson assembly. The 456 following protocol enables to assemble two or three sgRNA expression cassettes in one 457
vector. If it is intended to clone more than three sgRNAs in one vector primer pairs have to 458 be designed with appropriate assembly overhangs, according to manufacturer guidelines. 459 
Feeder-free hiPSC culture conditions 519
Cultivation of high-quality human iPS cells requires optimal and aseptic conditions. 520
The cultures should be free of viral, mycoplasmic and bacterial contaminations and have a 521 normal karyotype. It is recommended to cultivate human iPSCs in antibiotic-free media to 522 avoid the overlooking of mycoplasma infections. Therefore, it is worth to emphasize the 523 importance of aseptic culture conditions. The optimal growth conditions for human 
Transfection of CRISPR/Cas9 constructs into hiPS cells 619
We suggest using unmodified hiPSC lines for editing of a single target gene (Workflow 620 A) or using hiPS cell lines expressing Cas9 under a strong doxycycline inducible promoter if 621 one intends to modify multiple genes simultaneously (Workflow B). In our laboratory we 622 generated several different hiPS cell lines carrying an inducible Cas9 in the safe harbor locus 623
AAVS1, based on Gonzales et al. [19] (cell lines available upon request). Instead of using the 624
M2rtTA transactivator we used the TRE-3G Tet-on transactivator that drives a stronger 625 expression upon doxycycline induction (Fig. 2C) . The inducible Cas9 system is a versatile 626 tool to generate complex genotypes in a one-step experiment (Fig. 2B) . Since the cells are 627 already equipped with Cas9, smaller plasmids carrying only the sgRNAs and a 628 reporter/selector have to be transfected transiently, which improves the transfection 629 efficiency (Fig. 5) . 630
An efficient transfection of a CRISPR nuclease and the sgRNA is indispensable for 631 successful genome editing. The choice of a certain transfection method depends upon its 632 efficacy in a hiPS cell line of interest as well as on the viability of the cell line, when exposed 633 to the transfection method. Generally small vectors < 8 kb can be more efficiently transfected 634 and induce less cell death than large vectors >8 kb (Fig. 5A and B) . However, where some 635 
679 680

Electroporation-based transient transfection using the Neon system 681
The following protocol describes the electroporation procedure using the 100 µl Neon 682 Transfection kit, aiming for a 6-well plate format. The DNA used should be of high quality to 683 achieve the optimal results. 684 685 1. Prepare highly concentrated plasmid DNA (1-5 µg/µl) in deionized water or TE buffer. 686
The amount of plasmid DNA should not exceed 10% of the total volume of 687 resuspension buffer. 688 2. Coat a 6-well plate with appropriate coating. 
FACS enrichment and clonal isolation hiPS cells 755
Selecting cells that were successfully transfected improves the rate of gene editing cells. In 756 this protocol, we describe the enrichment of transfected cells by FACS (Fig. 6) 
Analysis techniques of CRISPR/Cas9 induced modifications 838
There is a variety of methods to analyze genome modifications. Table 1 
PCR design 852
Depending on the analysis assay the requirements on the PCR reaction differ mainly in the 853 size of the PCR product. The major requirement for all analysis methods is a specific 854 amplification of the desired genomic locus. Therefore while designing the primers 855 heterozygous mutations or SNPs as well as repetitive sequences should be avoided. When 856 using Sanger sequencing followed by TIDE analysis the smallest recommended product 857 length is 250 bp. To guarantee adequate sequence decomposition, the sgRNA targeting site 858 should be 150 bp -400 bp distant from the sequencing primer binding site. For fragment 859 analysis, amplicon sizes ranging from 200-650 bp can be used to ensure a precise resolution 860 up to a single base. However, the smaller the amplicons are the higher the resolution will be. 861
For the RFLP assay the PCR should be designed in a way that product length should be in a 862 range of 400-1200 bp and the sgRNA target site is off-set of the amplicon center. 863 864
PCR reaction and purification 865
Genomic DNA (gDNA) can be extracted from hiPS cells of either a semi-confluent well of a 866 6-well plate or a confluent well of a 12-well plate with the Wizard (Promega) or other DNA 867 purification kits. PCR reactions are carried out using 100 ng gDNA in 50 µl with Herculase II 868 according to manufacturer's instructions. For Sanger sequencing or fragment analysis the 869 PCR products are gel purified using e.g. the Wizard SV Gel and PCR Clean-Up System 870 (Promega). 871 872
Sanger sequencing 873
Purified PCR products are prepared for sequencing using 20 pMol of sequencing primer and 874 60 -150 ng amplicon. The sequencing can be conducted by a commercial provider, e.g.
LGC 875
Genomics. 876 877
TIDE analysis 878
Tracking of Indels by DEcomposition (TIDE) is a method for quantitative assessment of 879 genome editing events (https://tide.nki.nl/) [48] . By aligning the sgRNA sequence to the 880 control sequence TIDE first identifies the expected Cas9 induced double-strand break site. 881
Based on the peak heights TIDE then analyzes the abundance of aberrant nucleotides over 882 the length of the sequence. The sequences are then evaluated with a decomposition 883 algorithm to identify the insertion and deletion mutations in the subjected sequencing file. an agarose gel, purified using a PCR Clean-Up System (Promega) and 60 -150 ng of the 898 purified samples are subjected to analysis (SMB Service GmbH, Berlin, Germany) using LIZ-899 500 size standard. 900 (1 %) where one clone was targeted on both alleles and the second clone on one allele. In 969 our next approach we transfected hiPSCs with combined vectors, coding for Cas9, the 970 sgRNA cassette as well as a fluorescent reporter (pU6-(BbsI)sgRNA_CAG-Cas9-venus-bpA 971 or pU6-(BbsI)sgRNA_CAG-Cas9_EF1-TagRFP). Using this strategy, we could enrich for 972 cells carrying Cas9 and the guide RNA. By this method we achieved a mutagenesis rate of 973 17 % in 116 analyzed clones. 70 % of the mutagenized clones were targeted on both alleles 974 and 30% only on one (Table 2; 
combined vector). 975
Based on these results, we conclude that when it is intended to introduce frameshift 976 indels in one single gene using transient transfection of Cas9 and sgRNA carrying 977 fluorescent reporter vectors (Workflow A) followed by FACS enrichment, 24 cell clones is a 978 reasonable number to obtain 2 to 4 clones with mutations on both alleles. 979 980 - Table 2 -981 982
Results obtained with Workflow B 983
In experiments where we used the doxycycline inducible Cas9 system with transient 984 transfection of fluorescent reporter vectors that express three different sgRNAs (Workflow B) 985 followed by FACS enrichment, we observed indel mutations in all three loci (Parkin, Dj1, 986 Pink1) in two out of 24 single cell derived hiPS cell clones (8 %). In one clone we detected 987 indels in two loci (4 %). None of the analyzed clones were mutated in only one locus. 71 % of 988 targeted loci were mutated in a bi-allelic manner (Table 3 ; Single round). 989
Additionally, we conducted an experiment where we followed Workflow B as described 990 above, but co-transfected the plasmid pCAG-Trex2-bpA to co-express the end-processing 991 enzyme Trex2. This experiment resulted in a targeting efficacy of 15 % for triple and 15 % for 992 double gene mutagenesis (20 clones analyzed in total). None of the analyzed clones were 993 mutated in a single locus only. Analogous to the previous experiments the majority of the 994 mutated loci were targeted on both alleles (Table 3 ; Single round +Trex2). 995
Finally we could improve the targeting efficacy by repeating the transfection and FACS 996 sorting procedure a second time (Table 3 ; Second round). In 15 of in total 57 single cell 997 derived human iPS cell clones we could detect triple gene mutagenesis (26 %). 7 clones 998 were targeted on two loci (12 %) and 4 clones carried indels in only one of the targeted loci 999 (7 %). In accordance with our previous observation the majority of mutations occurred on 1000 both alleles of a locus. 1001 - Table 3 -1002
1003
Thus we recommend based on our experience, when it is intended to introduce 1004 frameshift indels in multiple loci, we suggest using the doxycycline inducible Cas9 system 1005 
